Trump Unveils Ideas to End Surprise Bills, Calls on Congress
While reaching a consensus over health care seems increasingly harder these days in Washington, one priority both sides of the political aisle seem to agree on is stopping surprise billing. And President Donald Trump appears to be leading the charge.
Study Exposes Big Pharma’s Spending Habits
Research and development is the justification most commonly rattled off by Big Pharma when asked about rising drug prices. It takes money to investigate and develop these vitally needed drugs, they say. And while that part may be true, a recently released study found that drugmakers haven’t been entirely truthful with how they’re spending their money.
Lawsuit Alleging Coordinated Price Gouging Slapped Against 20 Pharma Companies
Price gouging, a coordinated attempt to hinder an investigation, destruction of evidence—no, this isn’t the plot of a summer blockbuster set to hit the big screen. It’s the reality of just the latest allegation against Big Pharma.
Republicans and Democrats Hope to Halt Drug Exclusivity
It seems like Big Pharma has a bag of tricks these days filled to the top with ideas and schemes to prevent drug prices from coming back down to Earth. Fortunately for American consumers, political heavyweights on both sides of the aisle are proposing ideas of their own to stop drugmakers’ attempts at stifling affordable medication.
Assignment of Benefits was a bad idea. Let’s hope it never comes back.
Assignment of Benefits (AOB) is an idea that rears its head periodically in the North Carolina General Assembly. This year it was put forward in House Bill 562 and could have cost North Carolinians as much as $2.2 billion in higher health care costs.
The myth of “patient wishes” and HB 562
HB 562, which could cost North Carolina as much as $2.2 billion, was rightfully not given a favorable report from the House Insurance Committee after a heated but respectful discussion from the members of the committee.